blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3238735

EP3238735 - CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF [Right-click to bookmark this link]
StatusExamination is in progress
Status updated on  17.06.2020
Database last updated on 24.08.2024
FormerRequest for examination was made
Status updated on  11.05.2018
FormerThe application has been published
Status updated on  29.09.2017
Most recent event   Tooltip27.02.2024New entry: Renewal fee paid 
Applicant(s)For all designated states
Eisai Inc.
200 Metro Blvd.
Nutley, NJ 07110 / US
[2023/52]
Former [2019/23]For all designated states
Eisai Inc.
100 Tice Boulevard
Woodcliff Lake, NJ 07677 / US
Former [2017/44]For all designated states
Morphotek, Inc.
210 Welsh Pool Road
Exton, PA 19341 / US
Inventor(s)01 / SENTISSI, Abdellah
1 Highrock Road
Dover, MA 02030 / US
02 / JACOBY, Douglas B.
34 Clovelly Road
Wellesley, MA 02481 / US
 [2017/44]
Representative(s)Atkins, James Gordon John, et al
Kilburn & Strode LLP
Lacon London
84 Theobalds Road
London WC1X 8NL / GB
[2017/44]
Application number, filing date17173578.004.02.2011
[2017/44]
Priority number, dateUS20100301615P04.02.2010         Original published format: US 301615 P
[2017/44]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report 
No.:EP3238735
Date:01.11.2017
Language:EN
[2017/44]
Search report(s)(Supplementary) European search report - dispatched on:EP06.07.2017
ClassificationIPC:A61K38/16, C07K14/435
[2017/44]
CPC:
C07K14/43522 (EP,CN,US); C07K14/195 (KR); A61K31/337 (EP,US);
A61K31/7068 (EP,US); A61K38/16 (KR); A61K47/60 (EP,US);
A61K47/6415 (EP,US); A61K51/088 (US); A61P13/08 (EP);
A61P15/00 (EP); A61P17/00 (EP); A61P19/02 (EP);
A61P25/00 (EP); A61P27/02 (EP); A61P29/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP);
A61P37/04 (EP); A61P9/00 (EP); G01N33/57415 (US);
G01N33/57434 (US); A61K38/00 (EP,US) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2018/24]
Former [2017/44]AL,  AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  RS,  SE,  SI,  SK,  SM,  TR 
TitleGerman:CHLOROTOXINPOLYPEPTIDE SOWIE KONJUGATE UND VERWENDUNGEN DAVON[2017/44]
English:CHLOROTOXIN POLYPEPTIDES AND CONJUGATES AND USES THEREOF[2017/44]
French:POLYPEPTIDES CHLOROTOXINES ET LEURS CONJUGUÉS ET UTILISATIONS[2017/44]
Examination procedure30.05.2017Date on which the examining division has become responsible
01.05.2018Amendment by applicant (claims and/or description)
01.05.2018Examination requested  [2018/24]
22.06.2020Despatch of a communication from the examining division (Time limit: M06)
04.01.2021Reply to a communication from the examining division
Parent application(s)   TooltipEP11740464.0  / EP2531206
Fees paidRenewal fee
30.05.2017Renewal fee patent year 03
30.05.2017Renewal fee patent year 04
30.05.2017Renewal fee patent year 05
30.05.2017Renewal fee patent year 06
30.05.2017Renewal fee patent year 07
27.02.2018Renewal fee patent year 08
27.02.2019Renewal fee patent year 09
27.02.2020Renewal fee patent year 10
25.02.2021Renewal fee patent year 11
25.02.2022Renewal fee patent year 12
27.02.2023Renewal fee patent year 13
27.02.2024Renewal fee patent year 14
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[A]WO03101474  (TRANSMOLECULAR INC [US], et al) [A] 1-15 * page 5, line 24 - page 6, line 6 * * page 10, paragraph 2 * * page 12, line 13 - line 21 * * page 13, line 26 - line 28; figure 10; example 11; claims 1-15; sequence 27 *;
 [A]WO2008088422  (AMGEN INC [US], et al) [A] 1-15 * abstract *;
 [A]US2009004105  (CHENG ZHEN [US], et al) [A] 1-15 * paragraph [0024] * * paragraph [0106] * * paragraph [0132] *;
 [E]WO2011142858  (HUTCHINSON FRED CANCER RES [US], et al) [E] 1-15 * claims 1-30; sequences 1-5 *;
 [A]  - TYTGAT J ET AL, "Purification and partial characterization of a 'short' insectotoxin-like peptide from the venom of the scorpion Parabuthus schlechteri", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19981228), vol. 441, no. 3, doi:10.1016/S0014-5793(98)01589-0, ISSN 0014-5793, pages 387 - 391, XP004258970 [A] 1-15 * figures 2,3 *

DOI:   http://dx.doi.org/10.1016/S0014-5793(98)01589-0
 [T]  - AKCAN MUHARREM ET AL, "Chemical re-engineering of chlorotoxin improves bioconjugation properties for tumor imaging and targeted therapy.", JOURNAL OF MEDICINAL CHEMISTRY 10 FEB 2011, (20110210), vol. 54, no. 3, ISSN 1520-4804, pages 782 - 787, XP002699206 [T] 1-15 * abstract *

DOI:   http://dx.doi.org/10.1021/JM101018R
by applicantUS5171741
 US5171749
 US5173504
 US5308608
 US5405957
 US5512675
 US5726304
 US5739116
 US5773001
 US5831088
 US5877296
 US5880145
 US5905027
 US5929105
 US6028174
 US6319891
 US6429187
 WO03010475
 WO03101475
 WO03101474
 US6667156
 US6870029
 WO2005099774
 WO2009021136
 WO2009117018
 WO2009140599
    - NOGRADY, Medicinal Chemistry A Biochemical Approach, OXFORD UNIVERSITY PRESS, (1985), pages 388 - 392
    - WAGNER; MUSSO, "New Naturally Occuring Amino Acids", AGNEW. CHEM. INT. ED. ENGL., (1983), vol. 22, pages 816 - 828
    - MERRIFIELD, "Solid-phase peptide synthesis", ADV ENZYMOL RELAT AREAS MOL BIOL., (1969), vol. 32, pages 221 - 96
    - FRIDKIN ET AL., ANNU REV BIOCHEM., (1974), vol. 43, no. 0, pages 419 - 43
    - "Concept and Early Development of Solid Phase Peptide Synthesis", METHODS IN ENZYMOLOGY, (1997), vol. 289, pages 3 - 13
    - SABATINO ET AL., "Advances in automatic, manual and microwave-assisted solid-phase peptide synthesis", CURR OPIN DRUG DISCOV DEVEL., (2009), vol. 11, no. 6, pages 762 - 70
    - "Guide to Protein Purification", DEUTSCHER ET AL., Methods in Enzymology, ACADEMIC PRESS, (1990), vol. 192
    - Y.S. ZHEN ET AL., J. ANTIBIOT., (1989), vol. 42, pages 1294 - 1298
    - M.D. LEE ET AL., J. AM. CHEM. SOC., (1987), vol. 109, pages 3464 - 3466
    - M.D. LEE ET AL., J. AM. CHEM. SOC., (1987), vol. 109, pages 3466 - 3468
    - W.M. MAIESE ET AL., J. ANTIBIOT., (1989), vol. 42, pages 558 - 563
    - M.D. LEE ET AL., J. ANTIBIOT., (1989), vol. 42, pages 1070 - 1087
    - A. KALOTA ET AL., CANCER BIOL. THER., (2004), vol. 3, pages 4 - 12
    - Y. NAKATA ET AL., CRIT. REV. EUKARYOT. GENE EXPR., (2005), vol. 15, pages 163 - 182
    - V. WACHECK; U. ZANGMEISTER-WITTKE, CRIT. REV. ONCOL. HEMATOL., (2006), vol. 59, pages 65 - 73
    - A. KOLATA ET AL., Handb. Exp. Pharmacol., (2006), vol. 173, pages 173 - 196
    - P. HERDEWIJN ET AL., ANTISENSE NUCLEIC ACIDS DRUG DEV., (2000), vol. 10, pages 297 - 310
    - Y. SHOJI; H. NAKASHIMA, CURR. CHARM. DES., (2004), vol. 10, pages 785 - 796
    - A.W TONG ET AL., CURR. OPIN. MOL. THER., (2005), vol. 7, pages 114 - 124
    - R.A STAHEL ET AL., LUNG CANCER, (2003), vol. 41, pages S81 - S88
    - K.F. PIROLLO ET AL., PHARMACOL. THER., (2003), vol. 99, pages 55 - 77
    - A.C. STEPHENS; R.P. RIVERS, CURR. OPIN. MOL. THER., (2003), vol. 5, pages 118 - 122
    - N.M. DEAN; C.F. BENNETT, ONCOGENE, (2003), vol. 22, pages 9087 - 9096
    - N. SCHIAVONE ET AL., CURR. PHARM. DES., (2004), vol. 10, pages 769 - 784
    - L. VIDAL ET AL., EUR. J. CANCER, (2005), vol. 41, pages 2812 - 2818
    - T. ABOUL-FADL, CURR. MED. CHEM., (2005), vol. 12, pages 2193 - 2214
    - M.E. GLEAVE; B.P. MONIA, NAT. REV. CANCER, (2005), vol. 5, pages 468 - 479
    - Y.S. CHO-CHUNG, CURR. PHARM. DES., (2005), vol. 11, pages 2811 - 2823
    - E. RAYBURN ET AL., LETT. DRUG DESIGN & DISCOV., (2005), vol. 2, pages 1 - 18
    - E.R. RAYBURN ET AL., EXPERT OPIN. EMERG. DRUGS, (2006), vol. 11, pages 337 - 352
    - I. TAMM; M. WAGNER, MOL. BIOTECHNOL., (2006), vol. 33, pages 221 - 238
    - C.A. STEIN ET AL., SEMIN. ONCOL., (2005), vol. 32, pages 563 - 573
    - S.R. FRANKEL, SEMIN. ONCOL., (2003), vol. 30, pages 300 - 304
    - S. GOEL ET AL., CLIN. CANCER RES., vol. 203, no. 9, pages 4069 - 4076
    - S.P. HENRY ET AL., ANTICANCER DRUG DES., (1997), vol. 12, pages 409 - 420
    - B.P. MONIA ET AL., PROC. NATL. ACAD. SCI. USA, (1996), vol. 93, pages 15481 - 15484
    - C.M. RUDIN ET AL., CLIN. CANCER RES., (2001), vol. 7, pages 1214 - 1220
    - J. KURRECK, EUR. J. BIOCHEM., (2003), vol. 270, pages 1628 - 1644
    - A. BIROCCIO ET AL., ONCOGENE, (2003), vol. 22, pages 6579 - 6588
    - Y. LEE ET AL., CANCER RES., (2003), vol. 63, pages 2802 - 2811
    - B. LU ET AL., CANCER RES., (2004), vol. 64, pages 2840 - 2845
    - A. RAIT ET AL., ANN. N. Y. ACAD. SCI., (2003), vol. 1002, pages 78 - 89
    - MCMANUS; SHARP, NATURE REV. GENET., (2002), vol. 3, page 737
    - ELBASHIR ET AL., GENES DEV., (2001), vol. 15, page 188
    - MILHAVET ET AL., PHARMACOL. REV., (2003), vol. 55, pages 629 - 648
    - F. BI ET AL., CURR. GENE. THER., (2003), vol. 3, pages 411 - 417
    - P.Y. LU ET AL., CURR. OPIN. MOL. THER., (2003), vol. 5, pages 225 - 234
    - I. FRIEDRICH ET AL., SEMIN. CANCER BIOL., (2004), vol. 14, pages 223 - 230
    - M. IZQUIERDO, CANCER GENE THER., (2005), vol. 12, pages 217 - 227
    - P.Y. LU ET AL., ADV. GENET., (2005), vol. 54, pages 117 - 142
    - G.R. DEVI, CANCER GENE THER., (2006), vol. 13, pages 819 - 829
    - M.A. BEHLKE, MOL. THER., (2006), vol. 13, pages 644 - 670
    - L.N. PUTRAL ET AL., DRUG NEWS PERSPECT., (2006), vol. 19, pages 317 - 324
    - T.R. BRUMMELKAMP ET AL., SCIENCE, (2002), vol. 296, pages 550 - 553
    - M.T. HEMMAN ET AL., NAT. GENET., (2003), vol. 33, pages 396 - 400
    - M. SCHERR ET AL., BLOOD, (2003), vol. 101, pages 1566 - 1569
    - M.J. LI ET AL., OLIGONUCLEOTIDES, (2003), vol. 13, pages 401 - 409
    - U. RITTER ET AL., OLIGONUCLEOTIDES, (2003), vol. 13, pages 365 - 373
    - T.F. LOU ET AL., OLIGONUCLEOTIDES, (2003), vol. 13, pages 313 - 324
    - T.R. BRUMMELKAMP ET AL., CANCER CELL, (2002), vol. 2, pages 243 - 247
    - G. YANG ET AL., J. BIOL. CHEM., (2004), vol. 279, pages 4339 - 4345
    - M. VAN DE WETERING ET AL., EMBO REP., (2003), vol. 4, pages 609 - 615
    - SIGGEL ET AL., J. PHYS. CHEM., (1996), vol. 100, pages 2070 - 2075
    - PETERSON ET AL., CANCER RES., (1996), vol. 56, pages 3980 - 3985
    - OMELYANENKO ET AL., INT. J. CANCER, (1998), vol. 75, pages 600 - 608
    - R.W. REDMOND; J.N. GAMLIN, PHOTOCHEM. PHOTOBIOL., (1999), vol. 70, pages 391 - 475
    - AMORINO ET AL., RADIAT. ONCOL. INVESTIG., (1999), vol. 7, pages 343 - 352
    - CHOY, ONCOLOGY, (1999), vol. 13, pages 22 - 38
    - SAFRAN ET AL., CANCER INVEST., (2001), vol. 19, pages 1 - 7
    - DIONET ET AL., ANTICANCER RES., (2002), vol. 22, pages 721 - 725
    - CIVIDALLI ET AL., RADIAT. ONCOL. BIOL. PHYS., (2002), vol. 52, pages 1092 - 1098
    - CHOY, ONCOLOGY, (2000), vol. 14, pages 7 - 14
    - MORNEX; GIRARD, ANNALS OF ONCOLOGY, (2006), vol. 17, pages 1743 - 1747
    - INANAMI ET AL., INT. J. RADIAT. BIOL., (2002), vol. 78, pages 267 - 274
    - TAMULEVICIUS ET AL., BR. J. RADIOLOGY, (1981), vol. 54, pages 318 - 324
    - PALCIC ET AL., RADIAT. RES., (1984), vol. 100, pages 340 - 347
    - MASUNAGA ET AL., BR. J. RADIOL., (2006), vol. 79, pages 991 - 998
    - RISCHIN ET AL., J. CLIN. ONCOL., (2001), vol. 19, pages 535 - 542
    - SHULMAN ET AL., INT. J. RADIAT. ONCOL. BIOL. PHYS., (1999), vol. 44, pages 349 - 353
    - BUCHHOLZ ET AL., INT. J. RADIAT. ONCOL. BIOL. PHYS., (1995), vol. 32, pages 1053 - 1058
    - SOGAARD ET AL., "Antibody- targeted superantigens in cancer immunotherapy", IMMUNOTECHNOLOGY, (1996), vol. 2, no. 3, pages 151 - 162
    - GIANTONIO ET AL., J. CLIN. ONCOL., (1997), vol. 15, pages 1994 - 2007
    - ALPAUGH ET AL., CLIN. CANCER RES., (1998), vol. 4, pages 1903 - 1914
    - CHENG ET AL., J. CLIN. ONCOL., (2004), vol. 22, pages 602 - 609
    - TERMAN ET AL., CLIN. CHEST MED., (2006), vol. 27, pages 321 - 324
    - PERABO ET AL., INT. J. CANCER, (2005), vol. 115, pages 591 - 598
    - BAGSHAWE ET AL., CURRENT OPINIONS IN IMMUNOLOGY, (1999), vol. 11, pages 579 - 583
    - WILMAN, "Prodrugs in Cancer Therapy", BIOCHEMICAL SOCIETY TRANSACTIONS, (1986), vol. 14, pages 375 - 382
    - "Prodrugs: A Chemical Approach To Targeted Drug Delivery", STELLA ET AL., Directed Drug Delivery, HUMANA PRESS, (1985), pages 247 - 267
    - ROOSEBOOM ET AL., PHARMACOL. REVIEWS, (2004), vol. 56, pages 53 - 102
    - The Handbook of Fluorescent Probes and Research Products, MOLECULAR PROBES, INC.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.